VMT Scientific, Inc. Announces Key Doctor Signs Agreement
November 07 2005 - 6:00AM
PR Newswire (US)
LAS VEGAS, Nov. 7 /PRNewswire-FirstCall/ -- VMT Scientific Inc.
(OTC: VMTF) VMT Scientific is proud to announce that Jacques D.
Barth, MD, PhD, FACC, FAHA has agreed to accept the position as
Primary Investigator (PI) for the VasCir(TM) program study to
culminate in FDA approval. Bryan McGlynn, VP of Medical Research
for VMT Scientific, with over thirty-five years of medical research
experience, will coordinate with Dr. Barth's efforts. Dr. Barth
stated he is excited about being part of this history making
technology known as the VasCir(TM). VMT Scientific is also looking
forward to its technology being scrutinized by Dr. Barth's advanced
vascular image processing technology. VMT Scientific is dedicated
to proving efficacy and educating Diabetics about the VasCir(TM)
device. We believe attracting and working with dedicated physician
researchers will enable VMT Scientific, Inc. to forge ahead towards
one day bringing this technology to the world. We encourage
everyone to visit our website http://www.vmtf.com/ and take our
virtual tour about this technology and its objectives in treating
peripheral vascular disease. This Press Release contains
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
You should not place undue reliance on these forward-looking
statements. These statements involve risks and uncertainties that
could cause actual results to differ materially from those
suggested in the forward- looking statements, particularly those
risks and uncertainties inherent in the process of developing,
manufacturing and distributing medical products and Clinical
trials. Factors that may cause such a difference include risks
related to VMT Scientific Inc.'s limited operating history, risks
associated with completing development and obtaining FDA medical
approvals, successful patent protection and prosecution, successful
sale of licensed technology nationally or internationally. VMT
Scientific technology will not meet with market acceptance, the
risk of future warranty and product liability claims, the
uncertainty of VMT Scientifics' future access to capital to sustain
operations, achieve profitability or continue as a going concern,
the failure by VMT Scientifics' to secure and maintain
relationships with suppliers, manufacturers and other third
parties, reliance on key employees, and dependence on intellectual
property. These forward-looking statements are based on information
and management's expectations as of the date hereof. Future results
may differ materially from our current expectations. DATASOURCE:
VMT Scientific, Inc. CONTACT: Catherine S. Ratelle, Director of
Operations at VMT Scientific, Inc., +1-702-990-3477, Web site:
http://www.vmtf.com/
Copyright